Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SEASONED LIFESCIENCE EXECUTIVE TO SPEARHEAD GLOBAL GOTOMARKET STRATEGY AS GINKGO AUTOMATION SCALES EXTERNAL SALES ACROSS BIOPHARMA, TECHBIO, AND NEW SCIENCEDRIVEN MARKETS WHILE CONTINUING TO SUPPORT INTERNAL PROGRAMS. BOSTON , AUG. 12, 2025 /PRNEWSWIRE/ -- GINKGOBIOWORKS (NYSE: DNA), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THE APPOINTMENT OF BRIANO'SULLIVAN AS HEAD OF COMMERCIAL FOR GINKGO AUTOMATION.

GINKGO AUTOMATION APPOINTS BRIANO'SULLIVAN AS HEAD OF COMMERCIAL TO ACCELERATE EXTERNAL GROWTH

GINKGO PROVIDES AN UPDATE ON ITS RESTRUCTURING, INCLUDING ACHIEVEMENT OF ITS EXPANDED $250 MILLION COST SAVINGS TARGETS BOSTON , AUG. 7, 2025 /PRNEWSWIRE/ -- GINKGOBIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED ITS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. THE UPDATE, INCLUDING A WEBCAST SLIDE PRESENTATION WITH ADDITIONAL DETAILS ON THE SECOND QUARTER, AS WELL AS SUPPLEMENTAL FINANCIAL INFORMATION WILL BE AVAILABLE AT INVESTORS.GINKGOBIOWORKS.COM.

GINKGO BIOWORKS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

PRESENTATION AND Q&A SESSION SCHEDULED FOR POST-MARKET ON THURSDAY, AUGUST 7, 2025 BOSTON , JULY 31, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT IT PLANS TO HOST A PRESENTATION AND Q&A SESSION REVIEWING BUSINESS PERFORMANCE FOR THE SECOND QUARTER ENDED JUNE 30, 2025, ON THURSDAY, AUGUST 7, 2025, BEGINNING AT 5:30 P.M. ET. THE PRESENTATION DETAILS AND WEBCAST LINK WILL BE AVAILABLE ON GINKGO'S INVESTOR RELATIONS WEBSITE AT HTTPS://INVESTORS.GINKGOBIOWORKS.COM , AND A REPLAY WILL BE MADE AVAILABLE.

GINKGO BIOWORKS ANNOUNCES DATE OF SECOND QUARTER 2025 RESULTS PRESENTATION

GINKGO WILL BUILD A PLATFORM DRIVEN BY ITS RECONFIGURABLE AUTOMATION CARTS (RACS) TECHNOLOGY TO ENABLE EMSL'S OPEN-ENDED EXPLORATION OF BIOCONOMY-RELEVANT MICROBES BOSTON , JULY 30, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT THE ENVIRONMENTAL MOLECULAR SCIENCES LABORATORY (EMSL) AT PACIFIC NORTHWEST NATIONAL LABORATORY (PNNL), A LEADING U.S. DEPARTMENT OF ENERGY OFFICE OF SCIENCE USER FACILITY, HAS SELECTED GINKGO AUTOMATION TO DELIVER A STATE-OF-THE-ART AUTOMATED ANAEROBIC PHENOTYPING PLATFORM AT ITS RICHLAND, WASHINGTON CAMPUS. THIS PURCHASE MARKS A SIGNIFICANT STEP IN EMSL'S MISSION TO ADVANCE FUNDAMENTAL BIOLOGICAL RESEARCH SUPPORTING U.S. ENERGY PRODUCTION, ENSURING LEADERSHIP IN THE BIOECONOMY, AND ESTABLISHING CRITICAL MATERIALS SUPPLY-CHAIN RESILIENCE.

GINKGO TO DEPLOY MODULAR AUTOMATION TECHNOLOGY TO THE ENVIRONMENTAL MOLECULAR SCIENCES LABORATORY (EMSL) AT PACIFIC NORTHWEST NATIONAL LABS (PNNL) TO ACCELERATE MICROBIAL RESEARCH FOR THE BIOECONOMY

STONY BROOK, NY / ACCESS NEWSWIRE / JULY 7, 2025 / APPLIED DNA SCIENCES, INC. (NASDAQ:APDN) (THE "COMPANY"), A LEADER IN PCR-BASED DNA TECHNOLOGIES, TODAY ANNOUNCED THAT ON JULY 2, 2025, IT RECEIVED WRITTEN NOTICE (THE "COMPLIANCE NOTICE") FROM THE NASDAQ STOCK MARKET LLC ("NASDAQ") INFORMING THE COMPANY THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2), WHICH REQUIRES THAT COMPANIES LISTED ON THE NASDAQ CAPITAL MARKET MAINTAIN A MINIMUM BID PRICE OF $1.00 PER SHARE, AND THAT THE COMPANY IS THEREFORE IN COMPLIANCE WITH THE NASDAQ CAPITAL MARKET'S LISTING REQUIREMENTS. NASDAQ ALSO NOTIFIED THE COMPANY IN THE COMPLIANCE NOTICE THAT THE HEARING BEFORE THE NASDAQ HEARINGS PANEL PREVIOUSLY SCHEDULED TO TAKE PLACE ON JULY 15, 2025, HAS BEEN CANCELLED, AND THE COMPANY'S SECURITIES WILL CONTINUE TO BE LISTED AND TRADED ON THE NASDAQ CAPITAL MARKET.

APPLIED DNA REGAINS COMPLIANCE WITH ALL NASDAQ CONTINUED LISTING REQUIREMENTS

LOS ANGELES--(BUSINESS WIRE)--GUESS?, INC. (NYSE: GES) IS PROUD TO ANNOUNCE THE RELEASE OF ITS FY20242025 ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG) REPORT TITLED IT'S IN OUR DNA. THE REPORT UNDERSCORES THE COMPANY'S CONTINUED DEDICATION TO SUSTAINABLE, RESPONSIBLE BUSINESS PRACTICES THROUGH ITS ACTION GUESS ESG STRATEGY  A FRAMEWORK DESIGNED TO IMAGINE, INNOVATE, AND INSPIRE ACROSS ALL FACETS OF THE ORGANIZATION. BUILT ON OVER A DECADE OF COMMITMENT TO ESG PRIORITIES, GUESS LEVERAGES GLOB.

GUESS UNVEILS FY20242025 ESG REPORT: IT'S IN OUR DNA  HIGHLIGHTING BOLD PROGRESS AND COMMITMENTS THROUGH ACTION GUESS STRATEGY

- CONDUCTS 27% WORKFORCE REDUCTION, CEASES OPERATIONS AT APPLIED DNA CLINICAL LABS, POSITIONS LINEARX FOR GROWTH - STONY BROOK, NY / ACCESS NEWSWIRE / JUNE 30, 2025 / APPLIED DNA SCIENCES, INC. (NASDAQ:APDN), A LEADER IN PCR-BASED DNA TECHNOLOGIES, ANNOUNCED A STRATEGIC RESTRUCTURING AND REALIGNMENT OF RESOURCES TO FOCUS EXCLUSIVELY ON ITS SYNTHETIC DNA MANUFACTURING BUSINESS, LINEARX. AS PART OF ACTIONS UNDERTAKEN, THE COMPANY IMPLEMENTED A WORKFORCE REDUCTION OF APPROXIMATELY 27% OF HEADCOUNT AND HAS CEASED OPERATIONS AT APPLIED DNA CLINICAL LABS (ADCL), A BUSINESS THAT PROVIDES MOLECULAR AND GENETIC TESTING SERVICES, EFFECTIVE JUNE 27, 2025.

APPLIED DNA SHARPENS STRATEGIC FOCUS ON SYNTHETIC DNA MANUFACTURING FOR BIOTHERAPEUTICS APPLICATIONS, CONSOLIDATES OPERATIONS BEHIND LINEARX

DIVISION OF SILVER SCOTT MINES, INC. EXPANDS HEALTH AND WELLNESS OFFERINGS FRANKLIN, NJ / ACCESS NEWSWIRE / JUNE 24, 2025 / SILVER SCOTT HEALTH, INC., A DIVISION OF SILVER SCOTT MINES, INC. (OTC PINK:SILS), TODAY ANNOUNCED A DISTRIBUTION AGREEMENT WITH DNA VIBE, THE INNOVATOR BEHIND PATENTED RED LIGHT THERAPY DEVICES. BEGINNING IN THE THIRD QUARTER, DNA VIBE'S WEARABLE WELLNESS TECHNOLOGY WILL BE AVAILABLE FOR PURCHASE ON THE SILVER SCOTT HEALTH WEBSITE, FURTHERING THE COMPANY'S MISSION TO BRING SCIENTIFICALLY-BACKED, NON-INVASIVE HEALTH AND WELLNESS SOLUTIONS TO CONSUMERS.

SILVER SCOTT HEALTH, INC. TO OFFER DNA VIBE'S AWARD-WINNING PATENTED LIGHT THERAPY DEVICES

PRESIDENT AND COO JUDY MURRAH APPOINTED NEW CHAIRPERSON OF THE BOARD OF DIRECTORS AND CEO STONY BROOK, NY / ACCESS NEWSWIRE / JUNE 17, 2025 / APPLIED DNA SCIENCES, INC. (NASDAQ:APDN) ("APPLIED DNA" OR THE "COMPANY"), A LEADER IN PCR-BASED DNA TECHNOLOGIES, TODAY ANNOUNCED THAT CHAIRPERSON AND CHIEF EXECUTIVE OFFICER DR. JAMES A. HAYWARD IS RETIRING FROM THE COMPANY AND WILL STEP DOWN FROM THE BOARD OF DIRECTORS EFFECTIVE JUNE 18, 2025, FOLLOWING A DISTINGUISHED 20-YEAR TERM.

APPLIED DNA ANNOUNCES RETIREMENT OF CHAIRPERSON AND CEO DR. JAMES A. HAYWARD

CLINICAL DATA HIGHLIGHT PLACCINE'S SIX-MONTH DURABILITY, TEMPERATURE STABILITY, AND MANUFACTURING ADVANTAGES OVER MRNA VACCINES

IMUNON ANNOUNCES PLACCINE DNA VACCINE TECHNOLOGY ABSTRACT SELECTED FOR ORAL PRESENTATION AT 10TH INTERNATIONAL CONFERENCE ON VACCINES RESEARCH & DEVELOPMENT

STONY BROOK, NY / ACCESS NEWSWIRE / JUNE 16, 2025 / APPLIED DNA SCIENCES, INC. (NASDAQ:APDN) ("APPLIED DNA" OR THE "COMPANY"), A LEADER IN PCR-BASED DNA TECHNOLOGIES, TODAY ANNOUNCED THAT IT WILL RESUME A REGULAR QUARTERLY INVESTOR CALL SCHEDULE, BEGINNING WITH THE RELEASE OF ITS FISCAL THIRD QUARTER 2025 FINANCIAL RESULTS IN MID-AUGUST 2025. IN ALIGNMENT WITH THIS RESUMPTION, THE COMPANY HAS CANCELLED ITS PREVIOUSLY SCHEDULED INTRA-QUARTER INVESTOR CALL FOR JUNE 17, 2025.

APPLIED DNA TO RESUME QUARTERLY INVESTOR CALL CADENCE BEGINNING WITH FQ3'25 FINANCIAL RESULTS REPORT IN MID-AUGUST

BOSTON , MAY 21, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA, "GINKGO" OR THE "COMPANY"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT MARK DMYTRUK, THE COMPANY'S CHIEF FINANCIAL OFFICER, INTENDS TO RESIGN FROM HIS ROLE AT THE COMPANY ON MAY 30, 2025 TO ACCEPT A POSITION AT ANOTHER ORGANIZATION AND STEVEN COEN, CPA, THE COMPANY'S CHIEF ACCOUNTING OFFICER, WILL BECOME CHIEF FINANCIAL OFFICER, EFFECTIVE UPON MR. DMYTRUK'S RESIGNATION.

GINKGO BIOWORKS ANNOUNCES APPOINTMENT OF STEVEN COEN AS CHIEF FINANCIAL OFFICER

GINKGO PROVIDES AN UPDATE ON ITS RESTRUCTURING, INCLUDING PROGRESS TOWARDS ITS EXPANDED $250 MILLION COST SAVINGS TARGET GINKGO AND PARTNERS AWARDED $29 MILLION CONTRACT BY ARPA-H TO DEVELOP DISTRIBUTED MANUFACTURING OF ESSENTIAL MEDICINES USING WHEAT GERM CELL-FREE EXPRESSION SYSTEMS BOSTON , MAY 6, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED ITS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. THE UPDATE, INCLUDING A WEBCAST SLIDE PRESENTATION WITH ADDITIONAL DETAILS ON THE FIRST QUARTER, AS WELL AS SUPPLEMENTAL FINANCIAL INFORMATION WILL BE AVAILABLE AT INVESTORS.GINKGOBIOWORKS.COM.

GINKGO BIOWORKS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

REPLACING ARTIFICIAL DYES WITH NATURAL COLORS HAS BECOME A NATIONAL PRIORITY, MOVED BY CONSUMER DEMAND, REGULATION, AND GOVERNMENTAL PRESSURE. ACHIEVING THIS MILESTONEBY INCREASING COLORING EFFICIENCY AND REDUCING COSTSCOULD UNLOCK NEW MARKET SEGMENTS THAT ARE NOT WELL-SUPPORTED BY CURRENT NATURAL FOOD COLORS.

PHYTOLON AND GINKGO BIOWORKS BOOST NATURAL FOOD COLORS BY HITTING FULL-PROJECT MILESTONE, NEARLY TRIPLING THE MANUFACTURING EFFICIENCY OF PHYTOLON'S INNOVATIVE COLORS

PRESENTATION AND Q&A SESSION SCHEDULED FOR POST-MARKET ON TUESDAY, MAY 6, 2025 BOSTON , APRIL 29, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT IT PLANS TO HOST A PRESENTATION AND Q&A SESSION REVIEWING BUSINESS PERFORMANCE FOR THE FIRST QUARTER ENDED MARCH 31, 2025, ON TUESDAY, MAY 6, 2025, BEGINNING AT 5:30 P.M. ET. THE PRESENTATION DETAILS AND WEBCAST LINK WILL BE AVAILABLE ON GINKGO'S INVESTOR RELATIONS WEBSITE AT HTTPS://INVESTORS.GINKGOBIOWORKS.COM , AND A REPLAY WILL BE MADE AVAILABLE.

GINKGO BIOWORKS ANNOUNCES DATE OF FIRST QUARTER 2025 RESULTS PRESENTATION

BOSTON , APRIL 22, 2025 /PRNEWSWIRE/ -- GINKGOBIOWORKS (NYSE: DNA), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT GINKGO AUTOMATION WILL DESIGN AND DEPLOY A RECONFIGURABLE AUTOMATION CART (RAC) SYSTEM TO AURA GENETICS, A HIGH-COMPLEXITY DIAGNOSTIC LABORATORY SERVICING THE GROWING AT-HOME TESTING AND WELLNESS MARKET. THIS ADVANCED MODULAR LABORATORY AUTOMATION PLATFORM WILL BE DEPLOYED AT AURA GENETICS' NEW 22,000-SQUARE-FOOT HIGH-THROUGHPUT FACILITY AT THE UPS HEALTHCARE LABPORT, LOCATED AT THE END OF THE RUNWAY AT THE LOUISVILLE, KY AIRPORT.

GINKO AUTOMATION PARTNERS WITH AURA GENETICS TO ACCELERATE DIRECT-TO-CONSUMER TESTING AND INNOVATION

GINKGO BIOWORKS AND PARTNERS AWARDED $29 MILLION CONTRACT BY ARPA-H TO DEVELOP DISTRIBUTED MANUFACTURING OF ESSENTIAL MEDICINES USING WHEAT GERM CELL-FREE EXPRESSION SYSTEMS BOSTON , APRIL 10, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS (NYSE: DNA), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED A NEW CONTRACT WITH THE ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H), ALONGSIDE PARTNERS TRITICA BIOSCIENCES , US PHARMACOPEIA (USP), ON DEMAND PHARMACEUTICALS , AND ISOLERE BIO BY DONALDSON . THIS TWO-YEAR PROGRAM, WHEAT-BASED HIGH EFFICIENCY ENZYME AND API TECHNOLOGY (WHEAT), AIMS TO ESTABLISH A NEW MANUFACTURING PROCESS FOR THE DISTRIBUTED PRODUCTION OF BIOLOGIC AND SMALL MOLECULE ACTIVE PHARMACEUTICAL INGREDIENTS (APIS) USING WHEAT GERM CELL-FREE EXPRESSION SYSTEMS.

GINKGO BIOWORKS TEAMS UP WITH PARTNERS ON ARPA-H PROJECT TO STABILIZE PHARMACEUTICAL SUPPLY CHAINS - USING AMBER WAVES OF GRAIN

CAMBRIDGE, MASS.--(BUSINESS WIRE)--PLEX RESEARCH IS PARTNERING WITH GINKGO BIOWORKS TO USE AI TO DEEPEN UNDERSTANDING OF THE MECHANISMS OF ACTION OF EXISTING DRUGS.

Ginkgo Bioworks Holdings, Inc.

DNA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ginkgo Bioworks Holdings, Inc.

DNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DNA